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Abstract
Background: Bacteriophages infecting lactic acid bacteria (LAB) are widely acknowledged as the
main cause of milk fermentation failures. In this study, we describe the surface-expression as well
as the secretion of two functional llama heavy-chain antibody fragments, one binding to the major
capsid protein (MCP) and the other to the receptor-binding proteins (RBP) of the lactococcal
bacteriophage p2, by lactobacilli in order to neutralise lactococcal phages.
Results: The antibody fragment VHH5 that is directed against the RBP, was fused to a c-myc tag
and expressed in a secreted form by a Lactobacillus strain. The fragment VHH2 that is binding to
the MCP, was fused to an E-tag and anchored on the surface of the lactobacilli. Surface expression
of VHH2 was confirmed by flow cytometry using an anti-E-tag antibody. Efficient binding of both
the VHH2 and the secreted VHH5 fragment to the phage antigens was shown in ELISA. Scanning
electron microscopy showed that lactobacilli expressing VHH2 anchored at their surface were able
to bind lactococcal phages. A neutralisation assay also confirmed that the secreted VHH5 and the
anchored VHH2 fragments prevented the adsorption of lactococcal phages to their host cells.
Conclusion: Lactobacilli were able to express functional VHH fragments in both a secreted and a
cell surface form and reduced phage infection of lactococcal cells. Lactobacilli expressing llama
heavy-chain antibody fragments represent a novel way to limit phage infection.
Background
Llamas, a member of the Camelidae family, produce heavy
chain antibodies, a type of antibodies that lack the CH1
domain and light chains [1]. The antigen binding portion
of these antibodies, called VHH, can be expressed at high
levels in Saccharomyces cerevisiae [2]. VHH antibody frag-
ments have already shown a considerable potential in sev-
eral biotechnological applications such as decreasing the
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amount of smooth surface caries in a rat model [3], short-
ening disease duration, severity and viral load in a mouse
model of rotavirus-induced diarrhea [4], and preventing
phage infection of Lactococcus cells during milk fermenta-
tion [5,6].
Virulent bacteriophages infecting lactic acid bacteria
(LAB) are widely acknowledged as the main cause of milk
fermentation failures and they are also responsible for the
downgrade of fermented dairy products such as cheeses
[7,8]. Their ubiquity in dairy environments, biodiversity,
and genomic plasticity are largely responsible for the dif-
ficulty in controlling phage infection [9,10]. Conse-
quently, several tactics have been proposed to curtail their
proliferation in industrial settings [10]. The generation of
phage neutralising VHH antibodies is one of the latest
antiviral strategies that have been proposed to inhibit lac-
tococcal phages [5,6]. As a proof of concept, a panel of
non-neutralising and neutralising VHH antibody frag-
ments targeting the lactococcal isometric-headed 936-
type phage p2, was recently obtained [5]. The direct addi-
tion of one of them (VHH5) to milk prevented the infec-
tion of the strain Lactococus lactis subsp. cremoris C2 by the
virulent phage p2 during the manufacture of a Gouda-
type cheese [6]. The VHH5 fragment effectively inhibited
lactococcal phage infection by directly binding to the
receptor-binding protein (RBP/ORF18) located at the dis-
tal part of the phage tail [5]. Recently, it was shown that
other phages belonging to the predominant lactococcal
936 species, could also be neutralised by this antibody
[11]. Moreover, some of the non-neutralising fragments,
such as VHH2, were shown to bind to the major structural
capsid protein (ORF11) of phage p2 [5].
Lactobacilli are also Gram-positive lactic acid bacteria that
normally colonize the oro-gastrointestinal tract [12,13].
Some Lactobacillus strains are believed to have health pro-
moting properties and are used as supplements in dairy
products, either alone or in combination with other
microorganisms [14,15]. Similarly to Lactococcus lactis
strains, other carefully selected Lactobacillus strains are an
integral part of industrial starter cultures that are added to
milk for the manufacture of an array of fermented dairy
products. Thus, their large-scale used in the food industry
is well established and their long history of safe use has
led to their status as a Generally Regarded As Safe (GRAS)
microorganism. This GRAS status has led to reports in
which lactobacilli were suggested as carriers for passive
immunization through surface expression or secretion of
various antibodies [16]. Recently, functional antibody
fragments targeting pathogenic bacteria (Streptococcus
mutans and Porphyromonas gingivalis) and a human virus
(rotavirus) have been produced in lactobacilli [4,16-18]
and shown to have an antimicrobial potential.
In this study, we have explored the possibility of produc-
ing functional VHH antibody fragments by lactobacilli in
order to neutralise lactococcal phages. The in situ VHH
production, in a secreted form or anchored to the cell sur-
face, could potentially alleviate the need to add the VHH
fragments directly to the fermentation medium, thereby
reducing the costs of the technology.
Results and discussion
Construction of Lactobacillus paracasei strains 
expressing VHH fragments that bind to structural proteins 
of Lactococcus lactis phage p2
We expressed the VHH5 single-chain as a secreted product
and the VHH2 as a surface anchored fusion protein in L.
paracasei. This strategy was selected because it was previ-
ously shown that the addition of VHH5 to a culture
medium prevented phage infection while VHH2 had no
effect [5]. However, we reasoned that anchoring VHH2 to
a cell surface might prevent phage infection by tittering
out viral particles present in a medium. First, the VHH2-E-
tag and VHH5-c-myc  fragments were inserted into the
Lactobacillus expression vector pLP401, respectively gener-
ating the vectors pLP402-VHH5-secreted and pLP401-
VHH2-anchored (Fig. 1A and 1B).
The presence of pLP402-VHH5-secreted in L. paracasei was
found to mediate the secretion of VHH5 into the medium
(Fig 1A). The introduction of pLP401-VHH2-anchored
into L. paracasei led to the cell surface expression of VHH2
by fusion to the C-terminal cell wall anchored domain of
proteinase P (Fig. 1B). In these vectors, the VHH expres-
sion is under the control of the promoter of the amy gene
(Fig. 1). This regulatable promoter is repressed by sugars
transported by the phosphoenolpyruvate-dependent
phosphotransferase systems (PTS). De-repression of the
promoter and protein expression is obtained by growing
the cells in the presence of non-PTS sugars such as manni-
tol. Both VHH fragments were tagged for detection with
anti-E-tag or anti-myc-tag antibodies. The theoretical
molecular mass of the anchored VHH2 and secreted
VHH5 is 43 kDa and 23 kDa respectively after cleavage of
the signal peptide (4 kDa) but containing the N-terminus
(26 amino acids, 3.9 kDa) of the amylase protein fused to
the VHH (Fig. 1).
Expression of the VHH fragments
VHH expression was analysed by immunoblotting of L.
paracasei-transformed strains using monoclonal anti-E-tag
antibodies or anti-myc antibodies. The culture superna-
tant and cell pellet of L. paracasei transformed with the
pLP402-VHH5-secreted vector contained a protein of 23
kDa corresponding to the secreted mature VHH (Fig. 2A).
An additional band of approx. 19 kDa in the supernatant
of  L. paracasei transformed with the pLP402-VHH5-
secreted could also be observed, probably resulting fromBMC Biotechnology 2007, 7:58 http://www.biomedcentral.com/1472-6750/7/58
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degradation. In all likelihood, the degradation did not
occur in the binding part of the VHH but rather in the N-
terminal part of the amylase protein fused to the VHH
after cleavage of the signal peptide (Fig. 1).
The cell extract of L. paracasei transformed with pLP401-
VHH2-anchored yielded a protein of approximatively 46
kDa (Fig. 2B). Surface expression of VHH2 on recom-
binant lactobacilli transformed with pLP401-VHH2-
anchored was analysed by flow cytometry using an anti-E-
tag antibody. The transformed pLP401-VHH2-anchored
L. paracasei strain showed a strong positive signal when
stained with the anti-E-tag antibody, whereas the same
parental strain transformed with the vector pLP402 did
not show any signal (Fig. 3). L. paracasei transformed with
pLP402-VHH5-secreted did not show any surface expres-
sion in flow cytometry (data not shown). Taken alto-
gether, these findings confirm the surface location of the
VHH2-E-tag-anchored fusion construct on the cell.
Using purified VHH5 and VHH2 fragments as positive
controls, we also estimated that the L. paracasei strain con-
taining the vector pLP401-VHH2-anchored expressed
about 103–104 molecules per cell (calculated from the
VHH standard) while the L. paracasei strain carrying
pLP402-VHH5-secreted, grown to an OD600  of 0.8,
expressed about 500 ng of VHH fragments per ml of
supernatant, corresponding to a production rate of
roughly 5 × 104 VHH fragments/bacterium/hour.
Binding of the expressed VHH fragments to phage p2
Binding of the VHH fragments to their respective antigen
was analysed by ELISA using homogenates of the L.
paracasei pLP401-VHH2-anchored and supernatant from
L. paracasei pLP402-VHH5-secreted. Both VHH fragments
were able to bind to their antigen indicating that they are
functional (Table 1). No activity was observed using
extracts and supernatants from cultures of L. paracasei con-
taining only the pLP402 vector. The Lactobacillus strain
expressing the anchored VHH2 was also mixed with Lac-
tococcus  phage p2 and analyzed by scanning electron
microscopy (SEM). Phage particles were found at the sur-
face of the recombinant lactobacilli expressing the
anchored VHH2 but not at the surface of L. paracasei con-
taining only the pLP402 vector (Fig. 4).
Determination of the expression of VHH fragments by L.  paracasei using Western blot assay Figure 2
Determination of the expression of VHH fragments 
by L. paracasei using Western blot assay. (A) lane 1, 
supernatant of pLP402; lane 2, supernatant of pLP402-VHH5-
secreted showing the secreted mature VHH of 23 kDa and a 
degradation product of 19 kDa; lane 3, cell extracts of 
pLP402-VHH5-secreted showing the precursor VHH (signal 
peptide-VHH) of 26 kDa and the mature VHH of 23 kDa. (B) 
lane 1, cell extracts of pLP401-VHH2-anchored showing a 
anchored VHH2 of 46 kDa; lane 2, control VHH2-E-tag 
(supernatant from pLP402-VHH2-secreted); lane 3; cell 
extracts of pLP402.
Map of the Lactobacillus expression vectors Figure 1
Map of the Lactobacillus expression vectors. (A) 
pLP402-VHH5-secreted with a stop codon (TAA) inserted 
after the E-tag sequence, mediating secretion of the antibody 
fragment and (B) pLP401-VHH2-anchored mediating surface-
anchored expression of antibody fragments by fusion to the 
last 244 amino acids of the Lactobacillus casei proteinase P. 
Pamy, Promotor sequence of the α-amylase gene of L. amy-
lovorus; SS amy, signal sequence of the α-amylase gene of 
Lactobacillus amylovorus (36 amino acids); N-terminus amy, N-
terminus (26 amino acids) of the α-amylase of L. amylovorus; 
deleted Tldh, remaining sequence after deletion of transcrip-
tion terminator of the lactate dehydrogenase gene of L. casei; 
VHH5, VHH fragment against the receptor-binding protein 
of lactococcal phage p2; VHH2, VHH fragment against the 
major structural capsid protein of phage p2; Anchor, anchor 
sequence from the proteinase P gene of L. casei (244 amino 
acids); Tcbh, transcription terminator sequence of the conju-
gated bile acid hydrolase gene of Lactobacillus plantarum 80; 
Ampr, ampicillin-resistance gene; Ery, erythromycin-resistance 
gene.BMC Biotechnology 2007, 7:58 http://www.biomedcentral.com/1472-6750/7/58
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Neutralisation of phage p2 by VHH2 and VHH5 expressed 
in lactobacilli
Finally, the ability of recombinant Lactobacillus strains to
neutralise p2 phages was also studied. A fixed titer of
phage (1,000 pfu) was mixed with supernatant or Lactoba-
cillus cells expressing VHH. The supernatant from Lactoba-
cillus  pLP402-VHH5-secreted was shown to neutralise
phage p2 by binding to its RBP and significantly inhibit-
ing (86%) its adsorption to the host strain Lactococcus lac-
tis MG1363. In comparison, almost no p2 phage particles
were bound to the parental L. paracasei strain with or with-
out the cloning vector pLP402 (Table 2). Interestingly, the
surface expressed VHH2 was also able to inhibit phage
infection of L. lactis cells, albeit to a lesser extent (31%)
(Table 2). Thus, even though VHH2 (which is recognizing
the major capsid protein) is non-neutralising when added
as a monovalent fragment to a culture medium [5,19], it
can neutralise bacterial viruses when anchored at the sur-
face of a lactic acid bacterium. As compared to other anti-
phage strategies currently available, the above reported
inhibitory effect of VHH (as a secreted or anchored prod-
uct) would probably not be considered as a strong anti-
phage system (7). However, lactic acid bacteria producing
VHH could be used concomitantly with other strategies to
increase the overall protection of starter cultures against
phages, thereby providing a novel hurdle to control them.
Conclusion
It was previously shown that VHH5 fragments bind to
some but not all 936-like phages [11], which is the most
prevalent lactococcal phage group in the dairy industry
[5,9]. Moreover, it was recently shown that phage mutants
no longer neutralised by VHH5 could be readily isolated
Table 2: Percentage of phage p2 inhibition by bacterially 
produced VHH
Bacteria % inactivationa
Supernatantb Bacteriac
L. paracasei parental 1.8 ± 5.9 2.1 ± 1.0
L. paracasei + pLP402 4.6 ± 4.0 -4.4 ± 6.4
L. paracasei + pLP402-
VHH5-secreted
86.0 ± 5.1 ND
L. paracasei + pLP402-
VHH2-anchored
3.4 ± 6.6 31.4 ± 2.8
a Mean ± standard deviation of at least three experiments
b 10 µl supernatant (approximately 5 ng VHH)
c 4 × 106 bacteria
Scanning electron microscope (SEM) image Figure 4
Scanning electron microscope (SEM) image. (A) Phage 
p2 particles binding to the recombinant L. paracasei express-
ing VHH2 anchored on the cell surface (approximately 20 
times more binding than the control). (B) Control, L. paraca-
sei containing only the vector pLP402 mixed with lactococcal 
phage p2. Arrows indicate the phage p2 particles. Bar = 1 
µm.
Flow cytometry showing VHH2 expression on the surface of  L. paracasei Figure 3
Flow cytometry showing VHH2 expression on the 
surface of L. paracasei. L. paracasei transformed with the 
pLP401-VHH2-anchored (black filled). The negative control, 
L. paracasei containing the vector pLP402, did not show any 
signal (grey line).
Table 1: Binding of the expressed VHH fragments to phage p2 
antigens by ELISA
Supernatanta Cell extractb
Dilutionc pLP402-
VHH5-
secreted
pLP402 pLP402-
VHH2-
anchored
pLP402
undiluted 0.987 0.076 1.549 0.084
1/4 0.519 - 1.207 -
1/16 0.339 - 0.511 -
1/64 0.128 - 0.215 -
a Supernatant from a culture grown until an OD600 nm of 0.8.
b Cell extract was made by sonication of 2.5 × 109 CFU in 1 ml of 
PBS.
c Undiluted or dilutions of supernatant and cell extract were added 
to the wells.BMC Biotechnology 2007, 7:58 http://www.biomedcentral.com/1472-6750/7/58
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in the laboratory [11]. Further strategies are thus needed
to improve the broadness of the VHH protection and to
prevent the emergence of new virulent phages. One possi-
ble approach could be the identification of more potent
neutralising VHH fragments. Alternatively, the expression
of multiple VHH fragments could enhance the protection
and the applicability of the system. It should be noted that
the VHH fragment should preferably be constitutively
produced using an expression system devoid of antibiotic
selection marker. Nonetheless, the proof of concept
reported here univocally showed that the expression of
anti-phage VHH by a LAB represents a novel tool to pre-
vent phage infection. This method would be much more
cost effective as the VHH fragments would be produced in
situ in the fermentation medium, eliminating the need for
additional purification of the VHH fragments.
Methods
Bacterial strains, phage, culturing conditions, and VHH 
expression
Escherichia coli DH5α was used as the cloning host strain
and cells were grown in Luria-Bertani (LB) medium (10 g
tryptone/litre, 5 g NaCl/litre, 5 g yeast extract/litre). E. coli
transformants were selected on LB plates containing 100
µg/ml ampicillin. Lactobacillus paracasei (previously
known as L. casei or L. zeae ATCC 393 pLZ15-) [20], trans-
formed with the plasmids pLP402 [16], pLP402-VHH5-
secreted or pLP401-VHH2-anchored, were selected on
MRS (Difco) plates with 3 µg/ml erythromycin after culti-
vation anaerobically at 37°C for 48 h. The pLP402-
VHH5-secreted and pLP401-VHH2-anchored vectors,
respectively mediated the secretion of VHH5 fragments
and the surface expression of VHH2 fragments under the
transcriptional control of the regulatable α-amylase pro-
moter. The α-amylase promoter is regulated by a negative
feedback. It is repressed by PTS sugars such as glucose and
lactose in L. paracasei. Growth in presence of non-PTS sug-
ars, such as mannitol, derepresses the promoter and acti-
vate gene expression. Pre-cultures of L. paracasei were
made by growing the cultures in LCM medium [21] sup-
plemented with 1% glucose and 3 µg/ml of erythromycin
when needed and incubating them at 37°C overnight.
These cultures were used to inoculate (2%) LCM-Man
medium supplemented with 0.5% mannitol and 3 µg/ml
of erythromycin, which were then incubated at 37°C.
Cells were harvested in the exponential growth phase at
an optical density at 600 nm (OD600) of 0.8 (108 cfu/ml)
[16,21]. Lactococcus lactis MG1363 was grown at 30°C in
M17 broth [22] supplemented with 0.5% glucose (GM17)
(Difco). Lysate of the lactococcal phage p2 was prepared
as described previously [23].
Construction of the Lactobacillus paracasei expression 
vectors pLP401-VHH2-anchor and pLP402-VHH5-secreted
The VHH2 encoding gene was cut out from the phagemid
vector pUR3824 [5] at the restriction sites SfiI and NotI
and ligated into pCANTAB 5E (Amersham Pharmacia Bio-
tech) in order to fuse it with the E-tag. PCR amplification
of the VHH2-E-tag was performed to add restriction sites
for ClaI and XhoI to the VHH2-E-tag using primers ClaI-
VHH: 5'-GCCATTGGAACTTACTCTGAAAA-3' and XhoI-
VHH: 5'-CCGCTCGAGTGCGGCACGCGGTTCC-3'. Simi-
larly, the VHH5-c-myc  fragment was amplified by PCR
from the pUR3825 [5] vector using the primers ClaI-VHH
and c-myc-stop (5'-CCGCTCGAGTTATGCGGCACGCG-
GTTCC-3') and adding in the process the restriction sites
ClaI and XhoI with a stop codon (TAA) after the c-myc
gene. The VHH2-E-tag and VHH5-c-myc fragments were,
after restriction cutting and purification, ligated into the
Lactobacillus expression vector pLP401 (previously named
pLP402) [16,21] at the ClaI and XhoI sites to generate the
vectors pLP401-VHH2-anchored and pLP402-VHH5-
secreted. Transformation of L. paracasei was performed as
previously described [16,21]. Selection of positive clones
was performed using MRS plates containing 3 µg/ml
erythromycin. Lactobacilli containing pLP402-VHH2-
secreted was also constructed, similarly to the pLP401-
VHH2-anchored construct but with a stop (TAA) before
the E- tag and was used as control in the Western blot
assays.
Preparation of samples for the enzyme-linked 
immunosorbent assay and Western blot analysis
After growth in presence of 0.5% mannitol, cells were
washed, treated with lysosyme and disrupted by sonica-
tion as previously described [17]. For ELISA, cell debris
were removed by centrifugation for 10 min at 10,000 × g
and the supernatant containing the protein extracts were
stored at -20°C before use. For the Western blot analyses,
Laemmli loading buffer was added to the sonicated cell
extracts and the samples were boiled for 5 min, centri-
fuged (15 min, 10,000 × g) after which the supernatants
were stored at -20°C. Supernatants from cultures of L.
paracasei secreting VHH5 were filtered (0.45 µm) and con-
centrated 50 times using an ultrafiltration unit (Amicon).
Protein concentrations were determined by the BioRad
protein assay (BioRad Laboratories). For Western blot, the
concentrated supernatant was boiled for 5 min in Lae-
mmli buffer.
Flow cytometry
After growth in presence of mannitol, 100 µl of each lacto-
bacilli culture (107  bacteria) containing the vectors
pLP402 or pLP401-VHH2-anchored were washed three
times in PBS by centrifugation (10,000 × g for 15 min)
before resuspension in 100 µl of PBS. An equal amount of
mouse anti-E-tag antibody (Amersham Bioscience)BMC Biotechnology 2007, 7:58 http://www.biomedcentral.com/1472-6750/7/58
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diluted 1/200 was added and the samples were incubated
on ice for 1 h. The washing procedure in PBS was repeated
and the samples were resuspended in 100 µl of PBS and
mixed with 100 µl cy2-labeled donkey anti-mouse anti-
bodies (Jackson Immunoresearch Laboratories) (final
dilution 1/200) and incubated on ice for 30 min. After
washing, the samples were resuspended in one ml of PBS
and analysed in a FACSCalibur machine (Becton Dickin-
son).
Western blotting
Samples were run on a 12% SDS-polyacrylamide gel and
transferred onto a nitrocellulose membrane (Hybond-
ECL, Amersham-Biosciences). The membranes were
blocked with 5% (w/v) milk powder diluted in PBS-
Tween 20 (0.05% v/v) (PBS-TM) and incubated for 1 h at
room temperature with monoclonal mouse anti-myc
9E10 (Abcam Inc.) for VHH5-secreted or anti-E-tag anti-
bodies for VHH2-anchored, both diluted 1/1,000 in PBS-
TM, followed by HRP (horse radish peroxidase) labelled
goat anti-mouse antibodies (1/1,000) (DAKO) for 1 h.
The washed membrane was then developed with ECL Plus
Western Blotting Kit (Amersham-Bioscience) according to
the manufacturer's instructions.
Enzyme-linked immunosorbent Assay
First, 96-well (Maxisorp) plates were coated with 10 µg/
ml of recombinant major structural capsid protein (MCP,
the VHH2 antigen) or recombinant receptor-binding pro-
tein (RBP, the VHH5 antigen) [5] and left overnight at
4°C. After washing with PBS containing 0.05% Tween 20
(PBS-T), dilutions of the concentrated supernatants from
L. paracasei cultures secreting VHH5 as well as of the
extract from cells anchoring VHH2, were added and incu-
bated at room temperature for 1 h. Concentrated superna-
tants and cell extracts from cultures of L. paracasei
containing only the vector pLP402 were used as negative
controls. Purified VHH2 and VHH5 from E. coli, respec-
tively with an E-tag and a c-myc tag [5], were used in stand-
ard curves to evaluate the amount of VHH produced by
various L. paracasei transformants.
Plates were washed twice and a mouse anti-E-tag antibody
(1/1,000) was added to the wells previously incubated
with the extracts from L. paracasei VHH2-anchored. A
mouse anti-myc antibody 9E10 (1/1,000) (Abcam Inc.)
was added to the wells previously incubated with the puri-
fied VHH2 and VHH5 as well as supernatant containing
VHH5 secreted by L. paracasei cells. After 1 h incubation at
room temperature, plates were washed twice and an alka-
line phosphatase conjugated rabbit anti-mouse antibody
(1/1,000) (DAKO) was added to the plates. Following
incubation for 1 h at room temperature, diethanolamine
buffer (1 M, pH 10.0) containing 1 mg/ml of pNPP sub-
strate (Sigma-Aldrich) was added to the wells. The absorb-
ance was read at 405 nm in a Vmax Kinetic Microplate
reader (Molecular Devices).
Scanning electron microscopy (SEM)
A culture of L. paracasei anchoring VHH2 was washed in
PBS and 100 µl (106 bacteria/ml) was mixed with 500 µl
(5 × 1010 pfu/ml) of the lactococcal phage p2 and left at
room temperature for 1 h. The mixture was fixed in 2%
glutaraldehyde diluted in 0.1 M sodium cacodylate and
0.1 M sucrose, and finally added onto a 0.1 mg/ml poly-
L-lysine coated RC58 filter. After dehydration (70% etha-
nol 10 min, 95% ethanol 10 min, 99% ethanol 10 min),
the samples were sputtered and analysed by SEM (JEOL
JSM-820) at 15 kV.
Phage inhibition assay
The protocol for this assay was adapted from the lactococ-
cal 936-phage adsorption experiments of Geller et al. [24].
L. paracasei strains were grown to an optical density of 0.8
at 600 nm (OD600) in LCM-Man medium containing the
appropriate antibiotic. Cells were harvested and the
supernatant was filtered (0.45 µm) for immediate use.
Cell pellets were suspended in 0.25 volume of LCM.
Approximately 1,000 plaque-forming unit (pfu) of lacto-
coccal phage p2 (30 µl) were mixed on ice with 10 µl of L.
paracasei supernatant (about 5 ng VHH5), cells (4 × 106
bacteria) or LCM. After incubation of 4 h on ice, the mix-
ture was centrifuged 5 min at 16,100 × g at 4°C. Phage
titer was determined as followed in triplicate using 10 µl
of the supernatant. Ten µl were added to 3 ml of GM17
supplemented with 0.75% agar and containing 100 µl of
an overnight culture of the host strain Lactococcus lactis
MG1363. The mixture was then poured onto a GM17
plate (1% agar), incubated overnight at 30°C, and the
number of plaques were counted. The percentage of inhi-
bition was calculated by dividing the titer of the phage
with L. paracasei bacteria or supernatant by the phage titer
in LCM. The quotient was subtracted from 1 and multi-
plied by 100. The experiment was repeated at least three
times and the means were calculated for the pool of exper-
iments. Because the amy promoter is repressed by lactose,
co-culture of both strains in milk to test inhibition of
phage infection was not tested with the present system.
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